Poole v. Alpha Therapeutic Corp.

698 F. Supp. 1367, 1988 U.S. Dist. LEXIS 3464, 1988 WL 112623
CourtDistrict Court, N.D. Illinois
DecidedApril 13, 1988
Docket86 C 7623
StatusPublished
Cited by21 cases

This text of 698 F. Supp. 1367 (Poole v. Alpha Therapeutic Corp.) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Poole v. Alpha Therapeutic Corp., 698 F. Supp. 1367, 1988 U.S. Dist. LEXIS 3464, 1988 WL 112623 (N.D. Ill. 1988).

Opinion

MEMORANDUM AND ORDER

MORAN, District Judge.

Defendants move to dismiss five counts of plaintiffs’ eight-count complaint pursuant to Rule 12(b)(6) of the Federal Rules of Civil Procedure. These counts are as follows: counts III and VI state claims for relief based on strict products liability; counts II and V seek punitive damages, II under the Illinois Survival Act and V under the Illinois Wrongful Death Act; and count VIII asserts a claim on behalf of Peggy *1369 Poole for negligent infliction of emotional distress. Defendants also move for sanctions under Fed.R.Civ.P. 11. Since plaintiffs have failed to state a claim in all five counts defendants’ motion to dismiss is granted and we impose sanctions for plaintiffs’ inclusion of count V.

FACTS 1

From 1975 until 1987 Stephen Poole, a hemophiliac, purchased and injected into his body an antihemophilic factor, gener-ieally referred to as factor VIII. The anti-hemophilic factor was manufactured, processed, marketed, distributed and sold by defendants. As a result of defendants’ failure to perform screening and heat-treating tests, and their failure to warn decedent of the product’s risks, Stephen Poole contracted Acquired Immune Deficiency Syndrome (“AIDS”). Poole was diagnosed in March 1986 and died on July 10, 1987.

Originally, Stephen and Peggy Poole filed a complaint in the Circuit Court of Cook County against Alpha Therapeutic Corporation (“Alpha”), Armour Pharmaceutical Company (“Armour”) and Miles Laboratories (“Miles”). Defendants removed the case to federal court on diversity grounds in October 1986. Following removal, Travenol Laboratories (“Travenol”), a nondiverse party, was joined as a defendant. This court held that joinder of Tra-venol did not defeat subject matter jurisdiction. Poole v. Alpha Therapeutic Corp., No. 86 C 7623, slip op. (N.D.Ill. July 22, 1987) [available on WESTLAW, 1987 WL 15176]. After Stephen Poole died, Peggy Poole amended the complaint to continue the action as administrator of her husband’s estate.

DISCUSSION

I. Strict Liability (Counts III, VI)

Plaintiffs have asserted two tort claims based on strict liability. Defendants contend that the Illinois Blood Liability Act, 2 Ill.Rev.Stat. ch. lllVa, If 5101, et seq. (1985), bars these claims. We agree. Paragraph 5102 of the Act bars any strict liability claim involving the processing or distributing of blood derivatives and products, and provides that

[t]he procuring, furnishing, donating, processing, distributing or using human whole blood, plasma, blood products, blood derivatives and products, corneas, bones, or organs or other human tissue for the purpose of injecting, transfusing or transplanting any of them in the human body is declared for purposes of liability in tort or contract to be the rendition of a service by every person, firm or corporation participating therein, whether or not any remuneration is paid therefor, and is declared not to be a sale of any such items and no warranties of any kind or description nor strict tort liability shall be applicable thereto, except as provided in Section 3.

(Emphasis added) (footnote omitted).

Section 3 of ¶ 5103 provides that

[e]very person, firm or corporation involved in the rendition of any of the services described ... warrants to the person, firm or corporation receiving the service and to the ultimate recipient that he has exercised due care and followed professional standards of care in providing the service according to the current state of the medical arts, and in the case of a service involving blood or blood derivatives that he has rendered such service in accordance with “The Blood Labeling Act,” effective October 1, 1972.

(Footnotes omitted.)

The Blood Liability statute was enacted in response to the Illinois Supreme Court’s decision in Cunningham v. MacNeal Me *1370 morial Hospital, 47 Ill.2d 443, 457, 266 N.E.2d 897, 904 (1970). Glass, 32 Ill. App.3d at 238, 336 N.E.2d at 497. In Cunningham, 47 Ill.2d at 457, 266 N.E.2d at 904, a hospital that provided blood contaminated with hepatitis was held strictly liable. Thereafter, the legislature enunciated the policy behind the Blood Liability Act in ¶ 5101 3 which expresses a preference for encouraging scientific research and development by describing as “services,” rather than “sales,” the products of those engaging in such scientific activities, and by barring liability where there is no fault.

The Illinois legislature, in rejecting strict liability claims, determined that society’s interest in ensuring an adequate blood supply outweighs a plaintiff’s interest in bringing such a claim. The fact that almost all states have enacted blood shield statutes insulating blood service providers from strict liability claims demonstrates the nationwide acceptance of such policies. Comment, Hospital and Blood Bank Liability to Patients Who Contract AIDS Through Blood Transfusions, 23 San Diego L.Rev. 875, 882 n. 36 (1986). While the statutes often vary in language, courts interpreting them have uniformly held that they bar claims of strict liability. See Coffee v. Cutter Biological, 809 F.2d 191, 193 (2d Cir.1987); Doe v. Cutter Laboratories, CA-287-0113, slip op. at 4, — F.Supp. - (N.D.Texas, Feb. 5, 1988); Jones v. Miles Laboratories, No. C 86-13, slip op. at 4, — F.Supp. - (N.D.Ga., Dec. 28, 1987); McKee v. Miles Laboratories, 675 F.Supp. 1060, 1063 (E.D.Ky., 1987); Hyland Laboratories v. Superior Court of California, 175 Cal.App.3d 509, 516-17, 220 Cal.Rptr. 590, 594 (6th Dist.1985). Even in those states where blood shield statutes have not been implemented, courts have been unwilling to subject providers of blood to strict liability claims. E.g., Kozup v. Georgetown University, 663 F.Supp. 1048, 1059 (D.D.C.1987).

In Clark v. Alpha Therapeutic Corp., No. 87-5230, slip op. (S.D.Ill., Oct. 27, 1987), the court was confronted with a case similar to this one. There the plaintiff, a hemophiliac, used an antihemophilic factor manufactured by the defendant and subsequently contracted AIDS. The Clark court held that under the Illinois Blood Liability Act, the blood derivatives are “specifically exempt from any claims of strict liability.” Clark, slip op. at 2-3. While the court barred plaintiff’s strict liability claims, plaintiff was allowed to proceed on his claim that defendant negligently failed to warn him of the possibility of contracting AIDS. Id. at 6.

As in Clark,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Coca-Cola Bottling Co. v. Hagan
750 So. 2d 83 (District Court of Appeal of Florida, 1999)
Drury v. Baptist Memorial Hospital System
933 S.W.2d 668 (Court of Appeals of Texas, 1996)
Resolution Trust Corp. v. S & K CHEVROLET CO.
918 F. Supp. 1235 (C.D. Illinois, 1996)
Annette T. New v. Armour Pharmaceutical Company
58 F.3d 445 (Ninth Circuit, 1995)
Wadleigh v. Rhone-Poulenc Rorer, Inc.
157 F.R.D. 410 (N.D. Illinois, 1994)
Neal v. Neal
873 P.2d 881 (Idaho Court of Appeals, 1994)
John J. Marchica v. Long Island Railroad Company
31 F.3d 1197 (Second Circuit, 1994)
Tischler v. Dimenna
160 Misc. 2d 525 (New York Supreme Court, 1994)
Carroll v. Sisters of Saint Francis Health Services, Inc.
868 S.W.2d 585 (Tennessee Supreme Court, 1993)
Rhone-Poulenc Rorer Inc. v. Home Indem. Co.
832 F. Supp. 114 (E.D. Pennsylvania, 1993)
Rhone-Poulenc Rorer Inc. v. Home Indemnity Co.
832 F. Supp. 114 (E.D. Pennsylvania, 1993)
Marriott v. Sedco Forex International Resources, Ltd.
827 F. Supp. 59 (D. Massachusetts, 1993)
Faya v. Almaraz
620 A.2d 327 (Court of Appeals of Maryland, 1993)
Marchica v. Long Island Rail Road
810 F. Supp. 445 (E.D. New York, 1993)
Burgess v. Clairol, Inc.
776 F. Supp. 1278 (N.D. Illinois, 1991)
Corgan v. Muehling
574 N.E.2d 602 (Illinois Supreme Court, 1991)
In Re Air Crash Disaster at Sioux City, Iowa
734 F. Supp. 1425 (N.D. Illinois, 1990)

Cite This Page — Counsel Stack

Bluebook (online)
698 F. Supp. 1367, 1988 U.S. Dist. LEXIS 3464, 1988 WL 112623, Counsel Stack Legal Research, https://law.counselstack.com/opinion/poole-v-alpha-therapeutic-corp-ilnd-1988.